{
    "Trade/Device Name(s)": [
        "iHealth Align Gluco-Monitoring System (BG1)"
    ],
    "Submitter Information": "Andon Health Co., Ltd.",
    "510(k) Number": "K153286",
    "Predicate Device Reference 510(k) Number(s)": [
        "K133790"
    ],
    "Regulatory Class": "II",
    "Product Code(s)": [
        "NBW",
        "CGA",
        "JQP"
    ],
    "Summary Letter Date": "August 11, 2016",
    "Summary Letter Received Date": "August 15, 2016",
    "Submission Date": "November 5, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.1345",
        "21 CFR 862.2100"
    ],
    "Regulation Name(s)": [
        "Glucose test system",
        "Clinical Chemistry"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "iHealth Align Glucose meter (BG1)",
        "iHealth Gluco-Smart App mobile application"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical biosensor",
        "Amperometry"
    ],
    "Methodologies": [
        "Electrochemical detection"
    ],
    "Submission Type(s)": [
        "System",
        "Analyzer",
        "Reagent",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for iHealth Align Gluco-Monitoring System (BG1), a self-testing blood glucose monitoring system for use with Android and iOS mobile devices.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from various sites; intended for single-person self-testing at home to monitor diabetes control; not for diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}